# EDGAR Filing Document

**Accession Number:** 0001840706
**File Stem:** 0001840706-26-000052
**Filing Date:** 2026-3
**Character Count:** 8343
**Document Hash:** a650ab3e260b46fe0e0e913825c7448f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001840706-26-000052.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001840706-26-000052

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Puylaert Kevin
- **CENTRAL INDEX KEY:** 0002119354

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40627
- **FILM NUMBER:** 26766336

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ZA LA PIECE 12
- **CITY:** ROLLE
- **NON US STATE TERRITORY:** VAUD
- **PROVINCE COUNTRY:** V8
- **ZIP:** 1180
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SOPHiA GENETICS SA
- **CENTRAL INDEX KEY:** 0001840706
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** LA PIECE, CH-1180
- **CITY:** ROLLE
- **STATE:** V8
- **ZIP:** 00000
- **BUSINESS PHONE:** 41 21 694 10 60

**MAIL ADDRESS:**
- **STREET 1:** LA PIECE, CH-1180
- **CITY:** ROLLE
- **STATE:** V8
- **ZIP:** 00000

## Ex-24

![](poa_kevinpuylaert001.jpg)

POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that I, Kevin Puylaert, Chief Sales Officer of SOPHiA GENETICS SA (the "Company"), hereby appoints each of Elimara Brunetto, Jeffrey Atwater, Michael Bourque, Tom Moore, and Jennifer Marques Pereira (each, an "Attorney-in-Fact"), each acting individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution, to: 1. prepare, execute, and file with the SEC all reports required under Section 16 of the Securities Exchange Act of 1934, as amended, including Forms 3, 4, and 5, in connection with the undersigned's ownership of and transactions in the Company's securities (including stock options, RSUs, and shares acquired thereunder); and 2. take all such other actions as any Attorney-in-Fact deems necessary or appropriate in connection with the foregoing. The undersigned acknowledges that this Power of Attorney does not relieve the undersigned of any personal liability under Section 16, and that the undersigned shall promptly notify each Attorney-in-Fact of all reportable transactions in the Company's securities. This Power of Attorney shall remain effective until the undersigned ceases to be subject to Section 16 reporting obligations with respect to the Company or until revoked by written notice to each Attorney-in- Fact. Signature: /s/ Kevin Puylaert Printed Name: Kevin Puylaert Title: Chief Sales Officer Date: March 6, 2026

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Puylaert Kevin<br><sub>(Last) (First) (Middle)</sub><br>C/O SOPHIA GENETICS SA<br>LA PIECE 12<br><sub>(Street)</sub><br>ROLLE, SWITZERLAND 1180<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>SOPHiA GENETICS SA [ SOPH ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Sales Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 92419<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Share Option (Right to Buy) | <sup>(2)</sup> | 2029-02-08 | Ordinary Shares | 10000 | $4 | D |  |
| Share Option (Right to Buy) | <sup>(2)</sup> | 2030-06-25 | Ordinary Shares | 15000 | $4.21 | D |  |
| Share Option (Right to Buy) | <sup>(2)</sup> | 2031-01-28 | Ordinary Shares | 20000 | $6.31 | D |  |
| Share Option (Right to Buy) | <sup>(2)</sup> | 2031-07-22 | Ordinary Shares | 32264 | $18 | D |  |
| Share Option (Right to Buy) | <sup>(3)</sup> | 2032-03-30 | Ordinary Shares | 10191 | $8.36 | D |  |
| Share Option (Right to Buy) | <sup>(4)</sup> | 2033-04-03 | Ordinary Shares | 12968 | $4.72 | D |  |
| Share Option (Right to Buy) | <sup>(2)</sup> | 2033-11-21 | Ordinary Shares | 5921 | $3.86 | D |  |
| Share Option (Right to Buy) | <sup>(5)</sup> | 2034-04-02 | Ordinary Shares | 57165 | $4.96 | D |  |
| Share Option (Right to Buy) | <sup>(6)</sup> | 2035-04-02 | Ordinary Shares | 28409 | $3.29 | D |  |

---

### Footnotes:

(1) Includes 30,405 ordinary shares issuable upon settlement of five restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 40 ordinary shares from a March 30, 2022 grant vesting in equal monthly installments through March 30, 2026; (ii) 1,156 ordinary shares from May 18, 2022 grant vesting in equal quarterly installments through May 18, 2026; (iii) 2,640 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iv) 7,279 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (v)19,290 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.

(2) The share options are fully vested and exercisable.

(3) The share option vests and becomes exercisable as to 25% of the ordinary shares on March 30, 2023, and then in equal monthly installments through March 30, 2026.

(4) The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.

(5) The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.

(6) The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

**Remarks:**
Exhibit list - Exhibit 24 - Power of Attorney

**Signature:** /s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**